74440-82-7

Usage

Uses

Used in Pharmaceutical Research:
3-Iodo-5-methoxybenzoic acid is used as a building block in pharmaceutical research for the development of various drugs, particularly those with anti-inflammatory and anti-cancer properties. Its unique structure allows it to be a key component in the synthesis of these therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Iodo-5-methoxybenzoic acid serves as an important intermediate compound. Its presence of both methoxy and iodine atoms makes it a versatile building block for the creation of a wide range of organic molecules.
Used in Treatment of Parasitic Infections:
3-Iodo-5-methoxybenzoic acid has been studied for its potential properties in the treatment of parasitic infections. Its ability to target and combat parasitic organisms makes it a promising candidate for use in medicinal treatments.
Used in Coordination Chemistry:
3-Iodo-5-methoxybenzoic acid has been investigated for its role as a ligand in coordination chemistry. Its potential applications in this field include catalysis and materials science, where it can contribute to the development of new catalysts and materials with improved properties.
Used in Anticancer Applications:
3-Iodo-5-methoxybenzoic acid is used as an anticancer agent, contributing to the development of drugs that target and inhibit the growth of cancer cells. Its unique structure allows it to interact with biological targets, making it a valuable component in the fight against cancer.
Used in Drug Delivery Systems:
To enhance the therapeutic potential of 3-Iodo-5-methoxybenzoic acid, it has been incorporated into drug delivery systems. These systems aim to improve the compound's bioavailability, targeting, and overall effectiveness in treating various conditions, including cancer and parasitic infections.

Upstream product

• 217314-47-1 methyl 3-amino-5-methoxybenzoate 
• 717109-27-8 methyl 3-iodo-5-methoxybenzoate 
• 78238-12-7 3-methoxy-5-nitrobenzoic acid 
• 99-34-3 3,5-dinitrobenzoic acid 
• 74165-74-5 3-amino-5-methoxybenzoic acid 

Downstream Products

• 1162259-51-9 N-benzyl-3-hydroxy-5-iodo-benzamide 
• 1162259-49-5 N-benzyl-3-iodo-5-methoxy-benzamide 
• 1162259-55-3 4-[3-[6-(3-benzylcarbamoyl-5-iodo-phenoxy)-hexyl]-2-(2-carboxy-ethyl)-phenoxy]-butyric acid 
• 1162259-53-1 4-[3-[6-(3-benzylcarbamoyl-5-iodo-phenoxy)-hexyl]-2-(2-ethoxycarbonyl-ethyl)-phenoxy]-butyric acid ethyl ester 
• 1162259-57-5 4-[3-[6-(5-benzylcarbamoyl-4'-methoxy-biphenyl-3-yloxy)-hexyl]-2-(2-carboxy-ethyl)-phenoxy]-butyric acid 

Relevant academic research and scientific papers

Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor

Monoacylglycerol lipase (MAGL) is the enzyme degrading the endocannabinoid 2-arachidonoylglycerol, and it is involved in several physiological and pathological processes. The therapeutic potential of MAGL is linked to several diseases, including cancer. The development of MAGL inhibitors has been greatly limited by the side effects associated with the prolonged MAGL inactivation. Importantly, it could be preferable to use reversible MAGL inhibitors in vivo, but nowadays only few reversible compounds have been developed. In the present study, structural optimization of a previously developed class of MAGL inhibitors led to the identification of compound 23, which proved to be a very potent reversible MAGL inhibitor (IC50 = 80 nM), selective for MAGL over the other main components of the endocannabinoid system, endowed of a promising antiproliferative activity in a series of cancer cell lines and able to block MAGL both in cell-based as well as in vivo assays.

Rational design of inhibitors of the bacterial cell wall synthetic enzyme GlmU using virtual screening and lead-hopping

An aminoquinazoline series targeting the essential bacterial enzyme GlmU (uridyltransferase) were previously reported (Biochem. J. 2012, 446, 405). In this study, we further explored SAR through a combination of traditional medicinal chemistry and structure-based drug design, resulting in a novel scaffold (benzamide) with selectivity against protein kinases. Virtual screening identified fragments that could be fused into the core scaffold, exploiting additional binding interactions and thus improving potency. These efforts resulted in a hybrid compound with target potency increased by a 1000-fold, while maintaining selectivity against selected protein kinases and an improved level of solubility and protein binding. Despite these significant improvements no significant antibacterial activity was yet observed within this class.

LEUKOTRIENE B4 INHIBITORS

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD.